Linagliptin: a thorough characterization beyond its clinical efficacy

Linagliptin: a thorough characterization beyond its clinical efficacy

Linagliptin, one of the five dipeptidyl peptidase-4 inhibitors available, has recently entered the market both in US and in most European countries for the treatment of type 2 diabetes mellitus. It presents a xanthine-based structure, and is characterized by unique pharmacokinetics, with non-linear...

Full description

Bibliographic Details
Main Authors:	Maria Angela eSortino, Tiziana eSinagra, Pier Luigi eCanonico
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-02-01
Series:	Frontiers in Endocrinology
Subjects:	Diabetes Mellitus GLP-1 Incretin DPP-4 inhibitors anti-diabetic drugs
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fendo.2013.00016/full

Similar Items

High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes
by: Tiziana eSinagra, et al.
Published: (2015-06-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01)

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
by: Gallwitz B
Published: (2010-05-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy
by: Anuj Kumar Borah, et al.
Published: (2022-05-01)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Incretin hormones as immunomodulators of atherosclerosis
by: Nuria eAlonso, et al.
Published: (2012-09-01)

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
by: Jorge F A Model, et al.
Published: (2022-06-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
by: Joanna Michałowska, et al.
Published: (2021-01-01)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
by: Rodrigo Daza-Arnedo, et al.
Published: (2021-11-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
by: Chia-Jen Tsai, et al.
Published: (2022-11-01)

Inflammation and Incretins
by: Amitabh Hatwal
Published: (2012-01-01)

A Localized Painful Rash Induced by Linagliptin in a Patient with type 2 Diabetes
by: İsmail Yıldız, et al.
Published: (2019-05-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
by: Sydney S. Wilbon, et al.
Published: (2023-12-01)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
by: Alina Babenko, et al.
Published: (2014-12-01)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
by: Derek Ge, et al.
Published: (2022-12-01)

The Anti-Inflammatory Effect of Novel Antidiabetic Agents
by: Panagiotis Theofilis, et al.
Published: (2022-11-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis
by: Carla Pelusi, et al.
Published: (2022-04-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
by: I. A. Bonda
Published: (2017-07-01)

BEYOND GLYCEMIC CONTROL IN DIABETES MELLITUS: EFFECTS OF INCRETIN-BASED THERAPY ON BONE METABOLISM
by: ELENA eCECCARELLI, et al.
Published: (2013-06-01)

Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea‐treated KCNJ11 neonatal diabetes
by: Pamela Bowman, et al.
Published: (2023-12-01)

Emerging role of antidiabetic drugs in cardiorenal protection
by: Wen-Jia Fu, et al.
Published: (2024-02-01)

A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
by: Ran Abuhasira, et al.
Published: (2021-12-01)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
by: Johansen Odd, et al.
Published: (2012-01-01)

Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study
by: Drs. Merel L.J.M. Janssen, et al.
Published: (2023-10-01)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley RE
Published: (2014-07-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)